Editorially reviewed · Last updated September 8, 2026 · How we review
Key findings
- The Wolverine stack is a nickname for combining BPC-157 with a product marketed as TB-500 for recovery.
- The FDA-reviewed TB-500 fragment has seven amino acids; it is different from full-length thymosin beta-4 used in some cited studies.
- July 2026 advisory recommendations concerned individual substances, not approval of a combination.
- No controlled clinical evidence establishes the marketed combination’s effectiveness or a dosing regimen for recovery.
- Adverse-event reports involving mixtures cannot isolate each ingredient’s contribution or establish an incidence rate.
- BPC-157 and thymosin beta-4 derivatives including TB-500 are prohibited under the 2026 WADA list.
The Wolverine Stack: BPC-157 + TB-500 Explained
Neither BPC-157 nor TB-500 is FDA-approved. The July advisory recommendations did not approve either drug or the combination. The current linked 503A Category 1 document lists neither substance; a prescription or online offer is not proof of a qualifying compounding pathway.
What Is the Wolverine Stack?
It's two separate synthetic peptides used at the same time, usually for injury or soft-tissue recovery:
Swipe sideways to see every column.
| Peptide | What it is | Marketed for | Human RCT evidence |
|---|---|---|---|
| BPC-157 | 15-amino-acid 'body protective compound' | Gut and tissue healing | Older enema-trial abstracts; no validated injury-recovery regimen |
| TB-500 | seven-amino-acid fragment of thymosin beta-4 | Systemic soft-tissue recovery | No clinical study of the exact fragment identified in FDA review |
What the FDA Votes Mean for the Stack
Both peptides cleared the Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026:
| Peptide | Reported PCAC recommendation | What it establishes |
|---|---|---|
| BPC-157 | 8–6, one abstention; recommended | No approval from this vote |
| TB-500 | Recommended; individual substance | No approval from this vote |
The advisory committee’s recommendations are non-binding. The final 503A Bulks List and FDA’s conditional Category 1 interim policy are different mechanisms; neither is drug approval. This review found no final rule adding these substances and no verified 12–24-month deadline. The committee did not review or approve a premixed BPC-157/TB-500 product.
The Evidence on the Combination
This is the single most important section, so it's blunt:
| Question | Answer |
|---|---|
| Controlled trial validating BPC-157 + TB-500 for injury recovery? | Not identified in the reviewed evidence |
| Human RCT on either peptide alone? | None completed for the recovery use case |
| Can separate-peptide experiments validate a blend? | No; identity, formulation and combined effects need their own evidence |
| Is a lower-dose blend proven safer? | No comparative safety evidence establishes this |
| Does one offset the other's side effects? | No evidence for this claim |
Circulating "Blend" Doses (No Clinical Validation)
A premixed vial introduces questions about each ingredient’s identity, concentration and compatibility. There is no comparative study establishing that a blend is the “riskiest form,” or that separate vials are safe.
Grey-Market Safety Risks
The evidence does not quantify how much combining these substances changes risk. Claims that contamination risk or dosing-error risk “doubles” are unsupported.
How This Relates to GLP-1 Drugs
Frequently Asked Questions
Is the Wolverine stack legal now?
Neither substance is FDA-approved, and the July advisory recommendations did not approve the combination. The final 503A list and interim-policy conditions must be checked separately; the current linked Category 1 document does not list either substance. No verified date for a final FDA decision is established here.
What is in a BPC-157 / TB-500 blend?
A "blend" is simply the two separate peptides — BPC-157 (a 15-amino-acid peptide) and TB-500 (a seven-amino-acid fragment of thymosin beta-4) — used together, sometimes sold pre-mixed in one vial. There is no standardized formulation; a seller's label does not establish the identity, content or quality of a particular product.
Is a pre-mixed BPC-157/TB-500 blend safe?
Safety is not established. A blend needs evidence for ingredient identity, concentration, compatibility and combined effects. The reviewed research does not establish that premixed vials are safer or riskier than separate products, and neither format is a validated treatment.
What is the dose for the Wolverine stack?
No clinical evidence reviewed here establishes a dose, ratio or cycle for BPC-157 plus TB-500 as an injury-recovery treatment. Community schedules and seller calculators cannot fill that evidence gap.
Does the Wolverine stack actually work?
No controlled clinical evidence reviewed here establishes that this exact combination improves injury recovery. Small BPC-157 reports, animal studies and research on full-length thymosin beta-4 do not validate the marketed TB-500 blend.
Why is it called the Wolverine stack?
It's a reference to the comic-book character's rapid healing factor — the combination is marketed as accelerating tissue repair. The July 2026 recommendations concerned the individual substances, not approval of the stack. The name is community slang, not a medical or regulatory term.
Sources
-
FDA. BPC-157 scientific briefing, July 2026.
-
FDA. TB-500 scientific briefing, July 2026.
-
FDA. 503A bulk-substance policy and category document.
-
U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov meeting page
-
World Anti-Doping Agency. 2026 Prohibited List. WADA
- What this is
- Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
- Regulatory status
- Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
- Our standard
- Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
- No commercial ties
- We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.
Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.
Sources
NEJM
The Lancet
JAMA
FDA
ClinicalTrials.govRelated reading
BPC-157: FDA 503A Vote, Legality & Safety
An advisory vote is not FDA approval. What the FDA briefing says about BPC-157 human evidence and current compounding status.
TB-500: FDA Review, Legality & Human Evidence
TB-500 is not FDA approved. The FDA review found no human effectiveness evidence; the reported committee vote remains unverified.
Are Peptides Legal in 2026? Inside the FDA 503A Vote Result
FDA advisory votes do not add peptides to the final compounding list. Current U.S. rules, evidence limits and GLP-1 distinctions.
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Research labels and purity claims do not establish product equivalence, approved dosing or legal exemptions.
Retatrutide Cost per Month and How to Access It
Every legitimate route to retatrutide today, open trials updated daily, Lilly's expanded access criteria, and what it may cost once approved.